Doximity, Inc.
DOCS · Healthcare
$26.35
Φόρτωση γραφήματος…
Νέα
Τελευταίοι τίτλοι για αυτή τη μετοχή
What Investors Should Know of This Doximity Officer's Latest Insider Transaction
Doximity's Chief Accounting Officer Siddharth Sitaram sold 5,652 shares worth $140,400 in mid-August. The transaction was driven by routine tax obligations from option exercises and restricted stock unit vesting rather than a loss of confidence in the company. Sitaram retains significant equity holdings of 93,122 shares. The sale reflects standard tax-driven liquidity management common among executives.
Doximity Handed Its President 150,000 Options Last Month. Here's What the Latest Filing Signals for Investors
Doximity's president Steven Zatz sold 4,482 shares worth $111,154 on August 15 through a routine tax withholding transaction upon restricted stock unit vesting. Zatz retains 51,864 directly held shares valued at $1.29 million, but his significant upside exposure comes from 150,000 options granted in July with a $20.49 strike price that don't vest until July 2027. The timing is notable given Doximity's recent earnings showed 7% revenue growth but margin compression due to higher-than-expected AI compute costs, with the CFO characterizing this as a 'good problem' as AI search revenue recognition is expected in Q3.
Doximity's New CFO Just Filed His First Form 4. Here's What Long-Term Investors Should Know.
Doximity's new CFO Matthew Sonefeldt sold 15,311 shares worth $380,000 in a non-discretionary transaction tied to restricted stock unit vesting and tax obligations. The sale reduced his holdings by only 3%, leaving him with a $12.1 million equity stake. The filing comes as the company faces slowing growth with Q3 guidance at only 1% growth midpoint, tight pharma spending, and margin pressure from AI compute costs, though management expects improvement in Q3 when AI search revenue lands.
Doximity's Co-Founder Just Filed a Form 4. Is There Anything in It Worth Worrying About?
Doximity CEO Jeffrey Tangney sold 8,505 shares (~$211,000) on August 15 to cover tax withholding on vesting equity awards—a non-discretionary transaction that reduced his holdings by only 0.3%. While the insider transaction itself is unremarkable, the underlying business faces headwinds: Q1 revenue grew just 7%, gross margins compressed due to AI compute costs, adjusted EBITDA fell 6%, and net income dropped significantly. The stock has cratered over 60% in the past year as the company invests heavily in AI with revenue recognition delayed until Q3.
Atlassian and Doximity Just Surged 30% After Earnings: 3 Software Stocks with the Same Setup
Atlassian and Doximity surged over 30% after earnings by exceeding low expectations with strong AI adoption. Three similar SaaS stocks—GitLab, UiPath, and Asana—have comparable setups with low expectations, high short interest, and emerging AI solutions that could drive significant post-earnings gains.